Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zimmer Biomet Holdings, Inc. (ZBH) on May 20, 2025, reporting events occurring on May 20, 2025, and May 27, 2025. The filing discloses the appointment of a new senior executive and the associated compensation arrangements.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Appointment
On May 27, 2025, the Company announced the appointment of Kevin Thornal to the newly created position of Group President, Global Businesses and the Americas, effective July 1, 2025. Concurrently, Mark Bezjak, President, Americas, will cease to be an executive officer of the Company upon Mr. Thornal's start date, though he will retain his office title.
Compensation and Employment Terms
Mr. Thornal's employment is on an at-will basis. The key financial terms of his appointment include:
- Base Salary: $850,000 annually.
- Target Bonus: 100% of base salary (prorated for 2025) under the Executive Performance Incentive Plan (EPIP).
- Equity Awards (2025):
- Restricted Stock Units (RSUs) with a grant date fair value of approximately $2,650,000, vesting ratably over three years.
- Performance-Based Restricted Stock Units (PRSUs) with a grant date fair value of approximately $2,650,000, with terms identical to the annual award granted in February 2025.
- Severance (Standard): Involuntary termination without cause entitles Mr. Thornal to one times the sum of base salary and target annual bonus, plus 12 months of COBRA premiums.
- Severance (Change in Control): Termination following a change in control (without cause or for good reason) entitles Mr. Thornal to two times the sum of base salary and target annual bonus, full vesting of equity, 24 months of COBRA premiums, and outplacement services.
Risks and Contingencies
The filing notes that severance payments are subject to the execution of a general release of claims. Additionally, Change in Control payments are subject to "golden parachute" excise tax rules (Section 4999), with payments adjusted to maximize the net after-tax result for the executive.
Investor Verification Checklist
- Verify the exact start date of July 1, 2025, and the immediate cessation of Mark Bezjak's executive officer status.
- Review the full text of the Offer Letter (Exhibit 10.1) and Change in Control Severance Agreement (Exhibit 10.2) for specific performance metrics tied to the PRSUs.
- Confirm the total potential payout under the Change in Control scenario, including the acceleration of equity and the specific calculation of the "largest aggregate annual bonus" for pre-change in control terminations.
- Check the 2025 Proxy Statement for details on the Executive Severance Plan and standard benefit arrangements referenced in the filing.